Fortis Malar

Why is Fortis Malar Hospitals Ltd falling/rising?

As of 22-Jun, Fortis Malar Hospitals Ltd's stock price is rising to 52.86, but it has declined 9.70% year-to-date and 27.04% over the past year, indicating a longer-term downtrend despite recent gains. Additionally, a 30.11% drop in delivery volume suggests decreased investor confidence, which may impact future performance.

As of 22-Jun, Fortis Malar Hospitals Ltd's stock price is rising, currently at 52.86, with a change of 0.64 (1.23%) upward. This increase comes after a trend reversal, as the stock has gained after two consecutive days of decline. Additionally, the stock has outperformed its sector by 0.55% today. <BR><BR>However, it is important to note that the stock has experienced a decline over longer periods, with a year-to-date decrease of 9.70% and a one-year drop of 27.04%. Despite this recent uptick, the stock remains lower than its 20-day, 50-day, 100-day, and 200-day moving averages, indicating that it is still in a longer-term downtrend. <BR><BR>Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 30.11% against the five-day average. This decline in trading activity may suggest a lack of confidence among investors, which could impact future price movements. Overall, while the stock is currently rising, the broader context shows significant challenges that could affect its performance moving forward.

Which are the latest news on Fortis Malar?

How big is Fortis Malar?

As of 10th June, Fortis Malar Hospitals Ltd has a market capitalization of 100.00 Cr, with recent net sales of 0.05 Cr and a net profit of 4.13 Cr. The latest balance sheet shows shareholder's funds of 30.21 Cr and total assets of 36.83 Cr.

As of 10th June, Fortis Malar Hospitals Ltd has a market capitalization of 100.00 Cr, classified as a Micro Cap.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.05 Cr and a Net Profit of 4.13 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 30.21 Cr and Total Assets of 36.83 Cr.

Who are in the management team of Fortis Malar?

The management team of Fortis Malar includes Daljit Singh (Chairman), Chandrasekar Ramasamy (Whole Time Director), and independent directors Ramesh L Adige, Ravi Rajagopal, and Shailaja Chandra, along with Sandeep Singh (Company Secretary & Compliance Officer).

The management team of Fortis Malar includes the following individuals:<BR><BR>1. **Daljit Singh** - Chairman & Non-Executive Director<BR>2. **Chandrasekar Ramasamy** - Whole Time Director<BR>3. **Ramesh L Adige** - Independent Director<BR>4. **Ravi Rajagopal** - Independent Director<BR>5. **Shailaja Chandra** - Independent Director<BR>6. **Sandeep Singh** - Company Secretary & Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Fortis Malar?

Fortis Malar's peers include Aashka Hospitals, Abate As Indust, Shanmuga Hospital, Soni Medicare, KK Shah Hospital, Maitreya Medica, Sangani Hospital, Nephro Care, KHFM Hospitality, and Aatmaj Health. Fortis Malar has below average management and growth ratings, with a 1-year return of -29.01%, significantly lower than Soni Medicare's 43.70%.

Peers: The peers of Fortis Malar are Aashka Hospitals, Abate As Indust, Shanmuga Hos., Soni Medicare, KK Shah Hospital, Maitreya Medica., Sangani Hospital, Nephro Care, KHFM Hospitality, and Aatmaj Health.<BR><BR>Quality Snapshot: Below Average management risk is observed at Aashka Hospitals, Abate As Indust, Fortis Malar, Soni Medicare, Maitreya Medica., KHFM Hospitality, and the rest. Average management risk is found at Shanmuga Hos. and Nephro Care, while Excellent management risk is noted at none. Below Average growth is seen at Aashka Hospitals, Abate As Indust, Fortis Malar, Soni Medicare, Maitreya Medica., KHFM Hospitality, and the rest, while Average growth is present at Shanmuga Hos., and Excellent growth is observed at Sangani Hospital and Nephro Care. Capital Structure ratings show Excellent at Shanmuga Hos., Good at KK Shah Hospital, Sangani Hospital, and Nephro Care, while Average is found at Aashka Hospitals, Abate As Indust, Fortis Malar, Soni Medicare, Maitreya Medica., KHFM Hospitality, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Soni Medicare at 43.70%, while Fortis Malar has the lowest at -29.01%. Fortis Malar's 1-year return is significantly lower than Soni Medicare's. Additionally, Aashka Hospitals, Abate As Indust, Shanmuga Hos., Soni Medicare, Maitreya Medica., KHFM Hospitality, and Fortis Malar all have negative six-month returns.

What does Fortis Malar do?

Fortis Malar Hospitals Ltd operates a multi-specialty hospital and is categorized as a micro-cap company. As of March 2026, it reported a net profit of 0 Cr and has a market cap of INR 100 Cr.

Overview:<BR>Fortis Malar Hospitals Ltd operates a multi-specialty hospital and belongs to the micro-cap category in the hospital industry.<BR><BR>History:<BR>The company was incorporated on April 12, 1989, originally as Malar Hospital Limited. It changed its name to Fortis Malar Hospital Limited on December 21, 2010. The latest quarterly results reported are for March 2026, showing a net profit of 0 Cr.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 100 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 24.00<BR>Industry P/E: 60<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.72<BR>Return on Equity: 12.02%<BR>Price-to-Book: 2.95<BR><BR>Contact Details:<BR>Address: Fortis Hospital Sector-62, Phase-VIII Mohali Punjab : 160062<BR>Phone: +91-172-5096001<BR>Email: secretarial.malar@malarhospitals.in<BR>Website: http://www.fortismalar.com

When is the next results date for Fortis Malar Hospitals Ltd?

The next results date for Fortis Malar Hospitals Ltd is 18 May 2026.

The next results date for Fortis Malar Hospitals Ltd is scheduled for 18 May 2026.

How has been the historical performance of Fortis Malar?

Fortis Malar has experienced a significant decline in financial performance, with net sales dropping from INR 144.59 crore in March 2019 to zero by March 2025, alongside severe reductions in profitability and total assets. The company faces critical liquidity challenges, highlighted by a net cash outflow of INR 107 crore in March 2025.

Answer:<BR>The historical performance of Fortis Malar shows significant fluctuations in its financial metrics over the years, culminating in a challenging situation in the most recent fiscal year.<BR><BR>Breakdown:<BR>Fortis Malar's net sales have seen a drastic decline from INR 144.59 crore in March 2019 to zero in March 2025, indicating a complete cessation of revenue generation. Total operating income followed a similar trend, dropping from INR 144.59 crore in March 2019 to zero in March 2025. The company reported an operating profit of INR 0.58 crore in March 2025, down from INR 11.21 crore in March 2023, reflecting a significant deterioration in profitability. The profit before tax also fell sharply, from INR 50.01 crore in March 2024 to INR 0.57 crore in March 2025. Consequently, the profit after tax dropped from INR 45.32 crore in March 2024 to INR 0.39 crore in March 2025. The company's total assets decreased from INR 188.33 crore in March 2020 to INR 36.83 crore in March 2025, while total liabilities also fell from INR 147.03 crore in March 2019 to INR 36.83 crore in March 2025. Cash flow analysis reveals a net cash outflow of INR 107 crore in March 2025, contrasting with a net inflow of INR 101 crore in March 2024, indicating severe liquidity challenges. Overall, the financial data reflects a troubling decline in Fortis Malar's operational and financial health over the years.

Are Fortis Malar latest results good or bad?

Fortis Malar's latest results show a mixed but generally positive trend, with improved profitability metrics despite a flat overall performance. While the company reported a negative Profit Before Tax, its Profit After Tax has significantly improved, surpassing last year's total within six months; however, the stock is currently rated as a 'Sell' by MarketsMOJO.

Fortis Malar Hospitals' latest financial results show a mixed but generally positive trend. While the overall performance for the quarter ending March 2025 was flat, there are notable improvements in profitability metrics. The company reported a Profit Before Tax (PBT) of Rs -0.37 crore, which, despite being negative, is the highest it has achieved in the last five quarters, indicating a consistent recovery.<BR><BR>Moreover, the Profit After Tax (PAT) for the last six months stands at Rs 0.37 crore, a significant turnaround from the previous year's PAT of Rs -3.24 crore. This suggests that Fortis Malar has already surpassed its profitability from the entire previous year within just half a year.<BR><BR>However, the stock is currently rated as a 'Sell' by MarketsMOJO, reflecting a cautious market sentiment despite the positive signs in profitability. Overall, while the results are not overwhelmingly strong, the recovery in profitability metrics indicates a positive trend for the company.

Who are the top shareholders of the Fortis Malar?

The top shareholder of Fortis Malar is Fortis Hospitals Limited, holding 62.71% of the shares, while individual investors collectively own 29.53%. Ruckmani Natarajan is the largest public shareholder with a 2.07% stake.

The top shareholders of Fortis Malar include Fortis Hospitals Limited, which holds the majority stake at 62.71%. There are no pledged promoter holdings, and the only mutual fund investment is from one scheme, accounting for 0.07%. Notably, Ruckmani Natarajan is the highest public shareholder with a stake of 2.07%. Additionally, individual investors collectively hold 29.53% of the shares.

Is Fortis Malar overvalued or undervalued?

As of April 25, 2023, Fortis Malar is considered a risky investment due to its high PE ratio of 139.64, negative profitability metrics, and poor return on capital employed, despite outperforming the Sensex year-to-date.

As of 25 April 2023, Fortis Malar's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company appears to be overvalued, given its high PE ratio of 139.64 and a negative EV to EBIT and EV to EBITDA of -56.94, which suggest significant concerns regarding profitability. Additionally, the return on capital employed (ROCE) stands at -17.23%, further highlighting operational inefficiencies.<BR><BR>In comparison to its peers, Fortis Malar's valuation metrics are considerably higher, with Max Healthcare at a PE of 100.29 and Apollo Hospitals at 69.03, both of which are more reasonably valued. The PEG ratio for Fortis Malar is 1.33, which, while not excessively high, does not compensate for the other concerning ratios. Notably, Fortis Malar has outperformed the Sensex year-to-date with a return of 22.85% compared to the Sensex's 5.63%, but this does not mitigate the overall valuation concerns.

What is the technical trend for Fortis Malar?

As of May 28, 2025, Fortis Malar's trend is mildly bullish, supported by moving averages and Bollinger Bands, despite mixed signals from the MACD and uncertainty indicated by Dow Theory.

As of 28 May 2025, the technical trend for Fortis Malar has changed from bullish to mildly bullish. The weekly MACD indicates a mildly bearish stance, while the monthly MACD remains bullish, suggesting mixed signals. The Bollinger Bands show a mildly bullish trend on both weekly and monthly time frames, and daily moving averages also reflect a mildly bullish outlook. The KST is bullish on both weekly and monthly charts, reinforcing some positive momentum. However, Dow Theory indicates no trend on both weekly and monthly time frames, suggesting uncertainty. Overall, the current stance is mildly bullish, driven primarily by the moving averages and Bollinger Bands, despite some bearish signals from the weekly MACD.

Has Fortis Malar declared dividend?

Yes, Fortis Malar Hospitals Ltd has declared a 25% dividend, amounting to ₹2.5 per share, with an ex-date of July 24, 2024. The company has demonstrated strong total returns across various periods, with a 5-year total return of 147.51%.

Fortis Malar Hospitals Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: 24 Jul 24<BR><BR>Dividend Yield: 3.36%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 17.45%, with a dividend return of 0%, resulting in a total return of 17.45%.<BR><BR>Over the past year, the price return was 32.75%, the dividend return was 4.05%, leading to a total return of 36.8%.<BR><BR>In the 2-year period, the price return was 43.73%, with a dividend return of 78.49%, culminating in a total return of 122.22%.<BR><BR>For the 3-year period, the price return was 39.14%, the dividend return was 79.44%, which resulted in a total return of 118.58%.<BR><BR>In the last 4 years, the price return was 13.67%, with a dividend return of 64.59%, giving a total return of 78.26%.<BR><BR>Over the 5-year period, the price return was 60.24%, the dividend return was 87.27%, leading to a total return of 147.51%.<BR><BR>Overall, Fortis Malar has not only declared a dividend but has also shown strong total returns across various periods, indicating positive performance in both price appreciation and dividend distribution.

Should I buy, sell or hold Fortis Malar?